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ABSTRACT 
The basic and fundamental role of Mg as being the second most abundant intercellular cation is established in various studies. It is 
identified as a divalent metal cofactor in over 300 enzymatic reactions involving energy metabolism and protein and nucleic acid 
synthesis. The biological function is identified in neuromuscular excitability. Mg ion regulates calcium ion flow in neuronal channels, 
helping to regulate neuronal Nitric Oxide production
1. Mg deficiency causes NMDA coupled Calcium channels to be biased towards 
opening, causing neuronal injury & neurological dysfunction, which may appear to humans as major depression. The present study 
confirms a reduction in the symptoms of depression found in the male population comprising of different age group by Mg treatment. 
CSF Mg has been found low in treatment resistant suicidal depression. Brain Mg is also low in TRD using phosphorous nuclear 
magnetic resonance Spectroscopy
2. A 2009 randomized clinical trial shows that Mg therapy was an effective as TCAs in depressed 
diabetics. Increase in brain Mg enhances both short term synaptic facilitation and long term potentiation and improves learning and 
memory function
3 The present study is based on findings that male subjects diagnosed as depressed showed a marked reduction in 
behavioral and somatic features of the disease after administration of Magnesium supplement. Physiological and somatic anxiety was 
also alleviated in a certain age group which displayed recovery from Insomnia and agitation. Suicidal tendency was also negative in 
all age groups. This study focuses on the behavioral and somatic responses pertaining to brain biochemical changes induced by 
Magnesium therapy. 
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1. INTRODUCTION 
The psychological and physical symptoms leading to specific behavioral and somatic features of major depression are 
identified and evaluated in this study for male patients comprising of three different age groups. The patients are classified 
as subject of either reactive/secondary depression or bipolar effective disorder. It is established that besides biological 
vulnerability  of  the  disease  to  be  inherited,  a  combination  of  genetic,  psychological  and  environmental  factors  are 
involved in depressive disorder, later episodes of illness typically are precipitated by only mild stress. 
The male patients included in the study were clinically diagnosed by DSM IV as patients of chronic  pain with 
major depression at the stage of diagnosis ,low CSF magnesium and calcium are involved in many processes related to 
depression.
4 Valid  studies have  confirmed  that  hypercalcemia  and  hypomagnesaemia  are  associated  with  depression
5 
based on the relationship of cations magnesium functions as a calcium antagonist. Serum and CSF ca/mg ratio are found 
to be elevated in depressed patients
6, whereas patients of chronic pain with depression identified with low levels of CSF 
magnesium offer considerable data bearing clinical significance. Magnesium is a natural ca channel blocker. clinically 
magnesium deficiency has been associated with cardiac arrthymia, hypertension, MI, stroke, anxiety, migraine, panic 
attacks, epilepsy, osteoporosis, immune dysfunction as well as chronic fatigue, acute musculoskeletal pain and reflex 
sympathetic dystrophy, all illnesses with high incidence of concomitant depression
7-10 
2. MATERIAL AND METHOD 
Thirty male patients were diagnosed with depression by a positive DSM IV test for depression
11 as well as MMPI and 
clinical evaluation. These patients were classified in three age groups for assessment and clinical assessment of specific 
features such as agitation, guilt feeling, psychomotor retardation, insomnia, anxiety, weight loss and hypochondria. These 
patients  were  also  subject  to  chronic  pain  with  depression.  The  patients  underwent  lumbar  puncture  as  part  of  an 
evaluation for headache or suspected meningitis and were found to demonstrate no physical or mental disorder. A low 
level of magnesium in the CSF was detected in all patients. 
The patients underwent standard measurement of cell magnesium by magnesium load test
12 all thirty patients were 
found  deficient  in  magnesium.  The  dietary  intake  of  the  patients  were  assessed  during  the  course  of  study  with  a 
comprehensive  food  frequency  questionnaire. The  thirty  patients  were  treated  with  a  daily  dose  of  oral  Magnesium 
Taurate for six weeks and psychomotor and psychological symptoms were carefully monitored. The patients were divided 
into three categories of age group. 
1) Age group 15-24      2)Age group 25-34     3)Age group 35-44 Pakistan Journal of Chemistry 2011 
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Table-1: Symptoms decreased /improvement (%) after treatment according to age 
S.No.  Symptoms  Age in years 
  15-24  25-34  35-44 
1.  Depressed Mood  16.7  16.7  62.5 
2.  Guilt Feeling  66.7  66.7  33.3 
3.  Suicidal Tendency  1.4  44.4  66.7 
4.  Insomnia(early, middle, late)  20.0  40.0  0.0 
5.  Work and Activities  40.0  57.1  33.3 
6.  Retardation-Psychomotor  50.0  66.7  50.0 
7.  Agitation  50.0  20.0  33.3 
8.  Anxiety Psychological  40.0  50.0  60.0 
9.  Anxiety Somatic  40.0  80.0  0.0 
10.  Somatic Symptoms GI  50.0  75.0  0.0 
11.  Somatic Symptoms General  0.0  0.0  0.0 
12.  Sexual Dysfunction/Menstrual Disturbance  80.0  20.0  50.0 
13.  Hypochondrias  0.0  25.0  0.0 
14.  Weight Loss  0.0  0.0  0.0 
15.  Insight  50.0  20.0  33.3 
 
3. RESULTS AND DISCUSSION 
Depressed mood was relieved in all the age groups and was markedly reduced in age group35-44 after oral magnesium 
intake. The group was labeled for treatment resistant depression (hereafter referred to as TRD), however the male patients 
exhibited  marked  reduction  of  behavioral  and  somatic  features  of  the  disease  after  administration  of  magnesium 
supplement. The response in male patients with TRD has been reported in previous studies as well
13 
Symptoms  of  guilt  feeling  were  much  reduced  in  age  group  15-24  and  group  25-34.  Both  the  age  groups 
demonstrated a better judgment of self-esteem after six weeks of magnesium therapy. It was also noted that diabetic males 
in each group found relief from the intense guilt feeling at early stage of magnesium supplementation. Some studies
14 
show that blood glucose levels cause flushing of different minerals along with magnesium sparing calcium. 
Suicidal  tendency  and  relishing  the  idea  of  suicidal  attempts  was  overall  resolved  in  all  the  patients.  Significant 
improvement  was  seen  in  age  group  15-24  after  magnesium  therapy.  A  previous  trial  has  shown  that  magnesium 
supplementation with varapamil reduces suicidal tendency in male patients with mania. 
Insignificant relief of insomnia is observed in all age groups.  Maximum improvement in work and activities was 
seen in age group 25-34.the erythrocytes and also plasma magnesium is shown to be associated with the intensity of 
depression. Blood hypomagnesaemia and CSF hypermagnesemia causes hyperexcitability in depressed people
15, further 
investigations  are  in  process  to  show  whether  hypermagnesemia  might  be  in  contrast  associated  with  psychomotor 
retardation as observed in depressed patients. After intake of oral magnesium supplements for six weeks psychomotor 
retardation was reduced in all the patients. Age group 15-24 also exhibited relief from agitation. psychological anxiety 
was relieved markedly in age group 35-44.whereas somatic anxiety was reduced in age group 25-34 markedly. This group 
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also  responded  to  magnesium  intake  by  showing  a  reduction  in  somatic  symptoms  GI.  General  somatic  symptoms 
however were not relieved. 
Sexual function was improved in age group 15-24. Hypochondrias was not relieved in any age group except for 
age group 25-34. There was no weight loss seen in any patient. Insight was improved the most in age group 15-24. the 
chronic pain with depression is reduced in each patient with an overall sensation of wellbeing. 
 
4. CONCLUSION 
On the basis of the study magnesium is found to  alleviate the physical and psychological symptoms of depression. 
Magnesiumtaurate  therapy  at  a  daily  dose  of  450mg  is  also  effective  in TRD  and  can  also  be  given  with  classical 
antidepressants for synergestic effects. Increased intake of magnesium rich food substances in patients of anxiety and 
depression is advised. The study of effect of magnesium therapy at different doses in depression or chronic depression 
with diabetes bears ample prospect and is open for study. 
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